Shares have a successful launch, debuting at a 46% premium on the list

Healthcare tech firm Indegene, Inc. is gearing up for its initial public offering (IPO) as it aims to raise capital to fund its growth and expansion plans. The company plans to use the funds raised from the issuance of fresh equities to repay debts of its subsidiary, ILSL Holdings, Inc., and to meet the capital expenditure requirements of both Indegene and the parent company.

Indegene, established in 1998, has been providing digital services to the life sciences industry for the past 25 years. The company specializes in offering a range of services including clinical trials, regulatory submissions, pharmacovigilance, complaints management, and sales & marketing support to biopharmaceutical, emerging biotech, and medical devices companies.

Prior to the IPO, Indegene raised ₹548.77 crore from anchor investors, including renowned names like Capital Group, Fidelity Investments, and Abu Dhabi Investment Authority. The anchor book saw strong participation from both domestic and international investors, reflecting confidence in the company’s growth prospects.

The IPO is expected to provide Indegene with the necessary capital to fuel its inorganic growth and further strengthen its position in the healthcare tech industry. With a strong track record and a solid client base, the company is well-positioned to capitalize on the growing demand for digital services in the life sciences sector.